Core Viewpoint - Citigroup maintains a positive outlook on Ark Health (06086), rating it as "Buy" with a target price of HKD 8.5 [1] Financial Performance - Ark Health forecasts revenue for the previous year to be between RMB 3.5 billion and RMB 3.55 billion, representing a year-on-year growth of 30% [1] - The company expects to turn a profit, with estimated earnings between RMB 7 million and RMB 10 million [1] - Citigroup believes the performance is generally in line with expectations, having previously predicted a 28% revenue growth for 2025 and a net profit of RMB 6 million [1] Growth Drivers - Management attributes the rapid revenue growth to an increase in the number of patients and doctors on the platform [1] - The return to profitability is mainly due to revenue expansion and a reduction in share-based compensation expenses [1] Market Reaction - Ark Health's stock opened significantly higher by 10.25%, reaching a peak of HKD 4.19 [1] - The stock closed at HKD 4.01, reflecting a 41.7% increase, with a trading volume of 118 million shares and a total transaction value of HKD 452 million [1]
花旗：方舟健客(06086)盈喜符预期 评级“买入”目标价8.5港元